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Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central
nervous system. It attacks people from age 20–50 years old and the females' attacks
double than males' attacks. MS is an autoimmune disease affecting principally the central
nervous system that cause nerve sheath demyelination followed by axon damage and
paralysis. MS symptoms include muscle weakness, weak reﬂexes, muscle spasm, difﬁcult
in move, miss-coordination and unbalance with others. There are many factors may be
responsible for MS: microbial, viral, smoking, stress, environmental toxins, contaminated
diet, and gout. MS is wide spread in the populations in North Europe and this related to
lack of vitamin D due to decrease of sunlight exposure. MS biomarkers include nitric
oxide, interleukin-6, nitric oxide synthase, fetuin-A and osteopontin. MS is not a genetic
disease where MS occurs when human leukocyte antigen system related genes are
changed in chromosome 6. The physiology of MS is monitored by activation of immune-
inﬂammatory, oxidative, and nitrosative stress pathways. MS is including two main steps:
(1) myelin sheath destruction and formation of lesions and, (2) inﬂammation. Four types
of MS can be distinguished: relapsing-remitting, primary progressive, secondary pro-
gressive and progressive relapsing. Nine treatments have been accepted for relapsing-
remitting MS type: interferon b-1a, interferon b-1b, mitoxantrone, natalizumab, glatir-
amer acetate, ﬁngolimod, dimethyl fumarate, teriﬂunomide, and alemtuzumab, however,
the only treatment used is mitoxantrone for progressive MS but many of MS treatments
side effects are recorded. Complementary treatments also used in MS treatments such as:
vitamin D, Yoga, medicinal plants, oxygen therapy, acupuncture and reﬂexology.1. Introduction
Scientist Jean-Martin Charcot is the ﬁrst one who discovers
the disease in 1868 [1]. It is most famous and pronounced
autoimmune disease attacks the central nervous system [2].
According to world health organization reports in 2008;
actually 2–2.5 million with multiple sclerosis (MS) disease
were recorded in the world [3], and approximately 20000 MS
patients died all over the world in 2012 comparing to 12000
died in 1990 [4]. MS starts attacks people from age 20–50
years old and the records investigated that females' attacksdouble than males' attacks [5,6]. Disseminated sclerosis and
encephalomyelitis disseminate are two alternative names of
MS. The MS is autoimmune disease combined both genetic
and environmental factors such as viral-induced immune dis-
turbances [7]. There are many types of MS, sometimes occurring
in isolated neuron (relapsing type) or spreading to few or many
neurons (progressive type) [8]. The MS characteristic features are
common disability, moving limits, low personal activity-related
self-effectiveness, limitation of self-regulatory concepts, socio-
demographic factors restrictions, decline employment state, and
decrease educational level [9]. The MS symptoms may occur and
disappear completely where the permanent neurological
problems happen when the disease timely advances [8]. MS
symptoms occur when the nerve cells myelin sheath in the
central nervous system (brain and spinal cord) start to injure
and consequently damaged. MS is associated with many
symptoms and these include: physical, mental, and sometimes
psychiatric disturbances [10–12], due to the neural damage
occurs which block the communication among different parts
of the nervous system.under the CC BY-NC-ND license (http://
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Figure 1. MS main symptoms [30].
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summarized into two reasons: (1) the immune system destructed
the myelin sheath, and (2) failure of the myelin-producing cells
to produce new sheathes [13]. The two above mentioned two
reasons include numerous genetics and environmental factors
e.g. heredity, pollution, microbial and viral infections [11,14,15].
The MS is diagnosed depending on the present patient status
and the medical check-up investigations.
There are endogenous repair mechanisms to improve from
MS disease early phases and these repair mechanisms contains
inside local factors control these mechanisms. The natural killer
(NK) cells are quickly moved to the organs deﬁned by auto-
immunity and NK increasing numbers when inﬂammatory case
occurs. The NK cells are recalled in the brain subventricular
zone during the progressive type of MS in both humans and MS
animal model. These NK cells are establish very close sub-
ventricular zone neural stem cells (NSCs) so consequently the
cells begin to secret interleukin-15 and maintain the NK cells
function. Furthermore, the NK cells decrease the functional
capability of NSCs following MS inﬂammation so neurorepair is
found due to communication of both NK and NSCs cells [16].
There are different types of upper limb rehabilitation can be
found in MS incidence and a training program is run directed
toward the upper limbs improve limb function and structure
but cannot effect on the upper limb capability and
performance in MS patients [17].
There is no treatment for MS until now. All the MS treat-
ments try to attempt to improve the neuronal function following
MS occurs and stop any progress of the disease [11]. The use of
MS treatments in the early stage of MS can induce adverse side
effects and can be ineffective at all. The treatments with good
results are observed in teenager women where MS appears
early with relapsing type with few neurons damaged [18]. MS
decreases life with an average 5–10 years than other healthy
ones [10,19]. There are many treatments and diagnostic
procedures of MS are in the process of development.
2. MS symptoms
MS is an autoimmune disease affecting principally the central
nervous system (brain and spinal cord) that cause nerve sheath
demyelination followed by axon damage and consequently pa-
ralysis [20]. There are many and distinguished lesions found in
the lower urinary tract as pronounced symptoms in MS
patients [21]. On the other hand, MS is a major important
reason of disability of a neurological origin in the young
adults where depression is the most observed psychiatric
disorder in MS [22]. Central and peripheral auditory
disturbances are always appeared in MS [23]. On the other
hand, the typical optic neuritis is usually the presenting
symptom of MS [24]. The sleep disorder, exhaustion, and pain
interfering are among other symptoms associated with MS [25].
MS symptoms depend on the speciﬁc nerve attack in the
central nervous system andmay leadﬁnally to loss of sensitivity in
sensation such as muscle weakness, weak reﬂexes, muscle spasm,
difﬁcult in move; miss-coordination and unbalance with others;
problem in speech, optic problem, feeling tired, acute or chronic
pain, and bladder and bowel difﬁculties. Depression is always
associated with MS due to variable mood of MS patients. In
addition to, thinking and emotional problems are also observed in
MS. There are many factors increasingMS disease symptoms e.g.
viral infections such as cold, inﬂuenza, and gastrointestinalproblems. Females are more sensitive toMS thanmales especially
during 3 months after baby birth. Other factors do not effect on
MS to be found such as vaccination, breast feeding, and physical
status [10,25,26]. The expanded disability status scale (EDSS) is a
well-known test of MS-associated disability, in addition to,
other clinical investigations [27,28]. Stress also is a main cause of
MS [29]. Figure 1 reveals MS main symptoms [30].3. MS causes
Up to date, there are no reasons for MS incidence, however,
there is a combination of environmental and hereditary factors
including pollution, viral and bacterial infections, and stress may
be included. There are many factors may be responsible for MS
and these factors can be summarized into: microbial, viral and
other infections.
3.1. Microbial infection
The infection with microbes has been associated in the main
processes of introducing and increasing the incidence of MS [34].
MS can be induced by many microbes [11], where moving from
one place to another increase microbial infection to induce MS
[14,15].
The infectious disease (paratuberculosis) mainly affects wild
and domestic ruminants. This disease induced by Mycobacte-
rium avium paratuberculosis (MAP), where MAP correlated to
MS incidence. The MAP DNA was found in 4/7 (57.14%) goat,
and in 14/25 (56%) sheep cheese using qPCR. In goat, MAP
produced type S strain of MAP, and this MAP occurs in quan-
tities ranged from 1.8 × 104 to 6 × 104 MAP cells/g of cheese. In
this study, 56.57% and 66.60% of cheese tested showed positive
results for MAP and these can lead to increased incidence of MS
in human [35].
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Figure 2. Disability-adjusted life year for MS/100000 inhabitants in 2004
(Data from Death estimates for 2004 by cause for WHO Member States
(Persons, all ages), Multiple sclerosis world map.
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hypothesis and prevalence hypothesis. The hygiene hypothesis
assuming that microbial infection in early life is protective but
MS responses later to the early infection at the later person life
[10], while the prevalence hypothesis proposed that MS is due to
infection factors found in the region where a high proportion of
MS patients were recorded among population [14,15,36]. The
results obtained from MS patients support the hygiene
hypothesis other than the prevalence hypothesis [14,15].
3.2. Viral infection
Three evidences supported viral infection in MS: (1) presence
of oligoclonal bands in the central nervous system ﬂuid in MS
patients; (2) many viruses related to human demyelination
encephalomyelitis; (3) viral infection induced demyelination in
animals also [37]. The lymphocytic choriomeningitis virus is the
virus responsible for MS symptoms. The spreading of is
depending on MS concentration in the temperate zone, higher
occurrence away from the equator, and increased occurrence
in proximity to regions of highest MS rate, on the other hand,
there is no data about person-to-person transmission in MS
incidence [7].
3.3. Other infections
MS can be induced also by smoking and stress [14,15,38].
Environmental toxins may be also induced MS especially
exposure to solvents [38,39]. Contaminated diet and hormonal
intake may be related to MS [14,15]. Gout disease is not
reported in MS patients with lower uric acid levels in MS
which suggested a protective role of uric acid in MS [40]. MS
can be also induced through the dysregulation in the
neurovisceral incorporation of cardiovascular tone which can
lead to many MS-associated clinical symptoms. The MS
neurodegenerative and inﬂammatory progresses are disturbed
and can lead to the appearances of cardiovascular autonomic
nervous system dysfunction [41].
4. MS geography
MS is wide spread in the populations found in North Europe
and this related to lack of vitamin D due to decrease of sunlight
exposure so the child born inMay in North Europe has more resist
to MS than the same child born in November [14,15,42,43]. This
explained that the MS is presently the most common, and a
growing, main reason of neurological disability in young adults
in the Western world. The relation between vitamin D and MS
incidence are affected by a rise of MS incidence, a month of
birth effect, a relation of vitamin D with MS-associated genes
and this lead to a fact that high vitamin D levels associated with a
reduced MS risk [44]. There is a relation between places of birth
and MS so if the person travels to MS high risk region before
15 years old increase his sensitivity to MS attack than the same
person travel after 15 years old [10,38]. In 2010, MS patients
was 2–2.5 million (30 MS/100000) all over the world with
rates varying according to different regions as follow [3], in
Africa, MS rates less than 0.5/100000; in South East Asia, MS
rates 2.8/100000; in USA MS rates 8.3/100000; in Europe MS
rates 80/100000 and MS rates increase to 200/100000 in
Northern European countries [5,14,15,38].MS symptoms usually occurs in late twenties and early
thirties patients but it can in child and older patients over 50
years of age [3,5]. In child and youth patients, MS occurs in
females twice than males but in older patients above 50 years
old, MS appears equal in both males and females [45]. It
explained the geographical spreading of MS and its higher
ratio incidence in the northern places in Tehran, Iran and this
may be correlated to higher socioeconomic status of this
places [46]. Macroscopic and microscopic methods are used to
determine the occurrence and incidence of MS. Most studies
have focused on prevalent cases of MS but studies of MS
variation are more related for MS causes understanding.
There are 30 and 26 regions are detected MS incidence in
Manitoba, Canada; where three methods of detection are
used: (1) the circular spatial scan statistic, (2) the ﬂexible
spatial scan statistic, and the Bayesian disease mapping
(BYM) where the BYM method is the most effective method
than circular spatial scan statistic and ﬂexible spatial scan
statistic methods; where BYM method can at the same time
detect the geographical differences and MS disease control
[47]. In another study, the German statutory health insurance
reported 200000 identiﬁed with MS in Germany in 2014. MS
incidence is higher than expected where z49% of all MS
patients taken MS-speciﬁc drug treatments. MS patients live
in the east taken an average 30 daily doses per year less than
MS patients live in the western part. There are a regional
difference found in MS incidence and drug treatments [48].
The MS spreading in England is recorded by General
Practice Research Database where the MS percentage increased
annually by 2.4% however the MS equal to 285.8/100000 in
females and 113.1/100000 in males in 2010 although the
British government planned to decrease MS attacks to be
11.52/100000/year in females and 4.84/100000/year in males
by 2010. Females recorded 72% of MS incidence and males
equal to 71% of MS incidence. The highest MS incidence
percentage occurs in Scotland in the UK where 126669 MS
patients are recoded in the UK in 2010 (203.4/100000 popu-
lation) [49]. Figure 2 shows MS disability-adjusted life year for
MS/100000 inhabitants in 2004.
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Many laboratory markers play an important role for MS
diagnosis such as: nitric oxide, interleukin-6, nitric oxide syn-
thase, fetuin-A and osteopontin. Proteins represent nerve cell
injury e.g. N-acetylaspartate and neuroﬁlaments are also include
for MS markers [50]. Moreover, interleukin-4, ferritincarbonyl
protein, interleukin-10, interferon-g, interleukin-17, tumor ne-
crosis factor-a (TNF-a), plasma lipid hydroperoxides are among
MS biomarkers used [51]. The magnetic resonance imaging
(MRI) and positron emission tomography techniques can be
also used as MS markers [52], but MRI technique facing many
problems when apply in clinical application such as:
magnetization transfer, double-inversion recovery sequences,
functional magnetic resonance imaging and diffusion tensor [53].
On the other hand, there are other techniques are under
development such as: (1) technique measure inﬂammatory
markers, nerve dysfunction, and macrophages levels, (2)
technique measure iron excretion from the body, and (3)
technique measure cerebral perfusion [53] in MS patients (4)
radioactive tracers technique measure change in cortical
pathology, apoptosis, remylienation process and brain
inﬂammation [54], and (5) technique measure antibodies
against potassium channel are under advanced [55]. Figure 3
exhibits MRI technique as MS marker [31].Figure 3. MRI technique showing an iron deposit in a white matter lesion
(inside green box in the middle of the image [31].
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MS diagnosis related to patients' symptoms, MRI and labo-
ratory results [56], but MS can only diagnosed in late phase
[10,57]. The most known MS diagnosis is McDonald criteria
which combined laboratory, clinical and radiology reports of
lesions at different times in different body areas [3], in additionto, Schumacher and Poser criteria which the oldest known one
[58]. The cerebrospinal ﬂuid analysis, physical patients'
characters, and MRI are the most common diagnostic method.
MRI of the brain and spinal cord reveals the demyelination
area in MS where gadolinium injected intravenously to
discriminate the lesions areas [59,60]. MS associated
inﬂammation can be detected by cerebrospinal ﬂuid
investigation where immunoglobulin G tests are done where
immunoglobulin G inﬂammation marker occurs in 85% of MS
patients [59,61]. MS is always associated with visual and
sensory disturbances so optic and sensory clinical
investigations are important diagnosis in MS symptoms [62].
7. MS genetics
MS is not a genetic disease although there a lot of genetic
changes are responsible for MS symptoms [63]. MS increases
among the family of MS patient [11], however, MS rate
increases to 30% in identical twins while the rate 5% in non-
identical twins [10,64]. MS risk equal to 10 times higher than
normal in child in the case of both father and mother is
affected [5]. MS occurs when human leukocyte antigen (HLA)
system related genes are changed in chromosome 6 [10]. HLA
system related genes in chromosome 6 are related to other
autoimmune disease e.g. diabetes type I. The recent hereditary
researches proved that at least twelve genes outside HLA in
chromosome 6 are related to MS [65]. Pharmacogenetic-related
studies have been developed to treat MS, however, interferon-
b and glatiramer acetate showed the most successively, long-
action and safety drugs used in the therapy of MS all over the
world [66,67]. The omics technique and researches with
microRNAs have been done for discovering the change in
protein structure related with molecular mechanisms of MS so
many biomarkers can be developed and used in MS diagnosis.
The proteomic researches are preceding for detection of MS
biomarkers found in the bioﬂuids due to different
physiological processes occurred in MS incidence. The
microRNAs are very important complementary biomarkers
correlated to cellular damage occurring in MS patients [68].
The higher MS relapse incidence is recorded during warmer
months in different regions of the world so MS incidence is
correlated into cytokines secretion in different seasons. The
production of cytokines (interleukin-10, interleukin-6, and TNF-
a) are recorded in spring season and the cytokines secretion
increases from spring to summer particularly TNF-a and these
observations can help us in understanding the higher MS-clinical
activity [69].
Exogenous retroviruses are invaded into human cells so they
become part of human DNA and spreading over many genera-
tions and transformed into human endogenous retroviruses
(HERVs). The HERVs are silenced or expressed at low-levels,
but in some physiological disturbances circumstances such as
MS, HERVs expression becoming than normal cases. There are
three HERV are correlated to MS: (1) HERV-H, (2) HERV-K,
and (3) HERV-W. The MS-associated retrovirus protein
envelop (MSRV) from HERV-W is the strongest one in the
initiation of MS among the three above mentioned retroviruses
[70]. The MSRV performs two functions: (1) MSRV expression
in the peripheral immune cells, and (2) MSRV expression in
monocytes and microglia in central nervous system lesions in
MS patients, so it increases toll-like receptor 4 which stimu-
lates cytokines secretion, declines myelin protein expression,
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HLA region of chromosome 6 [32].HLA-A
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Figure 4. HLA region of chromosome 6. Changes in this area increase MS
probability [32].
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The patients with MS have a physiological disturbances
which lead to many of physical, mental and clinical disorders
such as (1) deterioration of body composition (changes in fat and
bone mass), (2) increased risk for diseases such as coronary
artery heart disease, non-insulin dependent diabetes mellitus,
lipid metabolism abnormalities, and osteoporotic fractures in
these patients. MS immobility leads to a changing pattern of
loading in the paralyzed areas, and secondary alteration in tissue
structure. However, bone and soft tissue changes in these pa-
tients are usually reported so the treating physicians must in-
crease the awareness of MS patients with respect to bone, bone
and fat loss, and their consequences aiming to obtain measures
to prevent bone and soft tissue loss in these patients [71].
The physiology of MS is monitored by activation of immune-
inﬂammatory, oxidative and nitrosative stress pathways. These
pathways include interleukin (IL)-1b, IL-4, IL-6, and IL-10;
peroxides; nitric oxide metabolites (NOx); albumin; ferritin; C-
reactive protein; and TNF-b and gadolinium-enhanced MRI scan
[72]. In a study comprisesMS patients with depression (n = 42) and
MS patients without depression (n = 108) and normal healthy
(n = 249). MS incapacity is measured using EDSS whiledepression in MS is evaluated using depressive subscale of the
Hospital Anxiety and Depression Scale in addition to the above
mentioned biochemical parameters. There are an increase in
IL-6 and decrease in IL-4 and albumin beside gastrointestinal
disorders and disease development in MS patients with
depression compared to MS patients without depression, in
addition, there is no relation between depression in MS patients
and oldness, body weight index, MS form, gender, MS persist,
and nicotine addiction, in the contrary, MS with depression is
related to MS development, peripheral inﬂammation, optical
and gastrointestinal disorders compared to MS patients without
depression [72].
The neuroactive steroids control and communicate the
physiology of the central and peripheral nervous system. They
exert neuroprotective effects and represent interesting and
promising trends for the therapeutic plans in MS disorders. The
sex variances in the neuroactive steroids levels are identiﬁed not
only under physiological conditions but are also detected in a
sex-dependent way in different physiological variations in MS.
The neuroprotective effects of neuroactive steroids, communicate
with the sex variation to control the neuroactive steroids levels and
this concept represents the basic to discover and produce a speciﬁc
neuroactive steroids used in neuroprotective treatments [73].
The depression scores in MS patients were inversely corre-
lated with: (1) the activity in the subgenual cingulate cortex; (2)
the functional connectivity between the hippocampus, orbito-
frontal cortex and the dorsolateral prefrontal cortex, and (3) the
functional connectivity between the amygdala and dorsolateral
prefrontal cortex. So the individual variation in depression in
MS patients is signiﬁcantly correlated with altered regional ac-
tivity and functional connectivity shapes within the limbic sys-
tem [74].
There are a relation between antiphospholipid antibodies and
MS where three non-classic antiphospholipid antibodies are
dominant in MS patients compared to healthy control ones.
These antibodies contain immunoglobulin M and immuno-
globulin G (IgG) against phosphatidylserine-b2GPI (PS-B2),
IgG prothrombin complex (PT–PT) and immunoglobulin M
prothrombin (PT). The good results obtained from different
antiphospholipid antibodies are PS-B2 IgG and PT–PT IgG. All
other antiphospholipid antibodies did not show any difference
between the MS patients and healthy control groups so conse-
quently a relation has been found between certain non-classic
antiphospholipid antibodies and MS incidence [75]. Tobacco
smoke induced changes in blood brain barrier physiology and
function and so caused major destruction on blood brain
barrier mechanisms such anti-inﬂammatory and immunity
pathways [76].
The mechanism responsible for initiation of lesion in MS still
undistinguishable, where there are two distinguished neuro-
pathological results have been found as an early physiological
process of MS: (1) microgalial nodules, and (2) newly forming
lesions. Both microgalial nodules and newly forming lesions do
not contain T cell inﬁltration or demyelination [77]. There are
small number of aggregated macrophages/microglia due to
damaged axons were reported in microgalial nodules result but
the oligodendrocyte apoptosis is the pronounced characteristic
step in the formation of new lesions. Both microgalial nodules
and newly forming lesions are mutually and synergistically
cooperate to induce MS [77].
The helper 1 cells, Th17, and regulatory T cells (Treg) are
produced by cytokines secreted in MS incidence. Many genes'
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19 different genes in relapses-remitting MS are changed before
and at 6, 12, 24, and 36 months of interferon treatments. All kind
of microRNA is changed during the interferon therapy where
higher interleukin-12Rb2 mRNA levels were correlated with
decrease risk of MS relapse [78]. Figure 5 shows physiological
sequences of MS incidence [33].Neuron Immune cells
Healthy myelin
Myelin destroyed by 
body’s own immune cells
Figure 5. Physiological sequences of MS incidence [33].
https://en.m.wikipedia.org/wiki/Multiple_sclerosisMS is including two main steps: (1) myelin sheath destruction
and formation of lesions in the central nervous system (brain and
spinal cord), (2) inﬂammation. The two steps are synergistically
communicate together to destroy the neuron tissue and lead toMS
[10]. In the other side,MS is an immune disease that appears due to
collaboration of person hereditary and environmental factors [11].
Destruction of neuron tissues is occurred due to attacks from
individual own immune system [10].
8.1. Myelin sheath destruction and formation of lesions
MS name means many injuries that found inside the nervous
system and these lesions occurred in the white matter inside the
visual neuron, basal ganglia, brain stem, and spinal cord. The
lesions may be found in the white matter tracts very near to the
lateral ventricles [10]. The white matter cells transfer neural
signals from grey matter area where information is collected
into the whole body, on the other hand, there is no lesions
formed in the peripheral nervous system [11].
Oligodendrocytes (cells create and maintain myelin sheath of
the neuron that transfers neural signals) are destroyed in MS [10],
so consequently the destruction of myelin sheath have lead
ﬁnally to break of the nerve axon. The destruction of myelin
sheath lead to no electrical signals transfer [11], and a repair
process is occurred in MS early phase this process named
remyelination but oligodendrocytes in MS advances cannot
rebuild the cells of myelin sheath and many lesions increases
in the central nervous system and ﬁnally remyelination process
is ineffective and many lesions appear covering damaged axon
of the neuron [79]. The resulting lesions are responsible for
MS symptoms [10]. There is an increase in astrocytes number
synergistically with the increase of lesions number, where
astrocytes accomplish many biochemical processes that
maintain the endothelial cells the form the blood–brain barrier,facilitate the nutrients transfer to the nervous tissue, support
the maintains of ion balance, and an important role in repair
process of brain and spinal cord [80].
8.2. Inﬂammation
Inﬂammation occurs simultaneously with the demyelination
process where T cells of the immune system causes inﬂamma-
tion [10], however, T cells direct into the brain through
interruption in the blood brain barrier where T cells consider
myelin sheath as a foreign body and began to attack it and
these cells named “autoreactive lymphocytes” [11].
Demyelin of neuron sheath stimulates inﬂammatory pro-
cesses to be activated and consequently immune cells begin to
release more cytokines and antibodies which causes more
damage of blood brain barrier and leading to activation of
macrophages and more activation of cytokines and other
destructive proteins [11]. Inﬂammatory processes decrease the
information transfer in the central nervous system through: (1)
cytokines and antibodies released halt neurotransmitters
produced by directed attack neuron, (2) cytokines and
antibodies produced increase destruction of myelin sheath, and
(3) increase cytokines and antibodies in the body lead to axon
damage totally [10]. The cytokines are important causes in the
initiation of many immune reﬂuxes. The interleukin-21 repre-
sents one of the major immune factors, inducing many immune
reﬂuxes by affecting on many immune cells. The interleukin-21
caused increased in autoimmunity through different mecha-
nisms, such as improvement and increased of helper T-17 and
follicular helper T (TFH) cells, initiation of NK cells, increasing
B-cell differentiation and antibody excretion and decreased of
regulatory T (Treg) cells. Furthermore, interleukin-21 has been
induced of autoimmunity process to be increased when treat-
ment of MS patients with alemtuzumab has occurred [81].
The inﬂammatory and apoptotic processes found in MS pa-
tients at the peripheral and central nervous system levels play an
important role in MS symptoms. There are a link between MS
phenomena and inﬂammatory and apoptotic processes occurring
in either the periphery or in the central nervous system in MS [82].
9. MS types
Four types of MS can be distinguished depending on MS
duration and future MS progression; this MS classiﬁcation is
important for treatment which is determined by US National MS
Society [8]. However, International MS panel in 2013 added
another two types: (1) clinically isolated syndrome, and (2)
radiologically isolated syndrome, but the four types are still the
main basic types [83], as follows: relapsing-remitting; primary
progressive; secondary progressive, and progressive relapsing.
9.1. Relapsing-remitting type
Relapsing-remitting type refers to unobservable relapses
staying for months or years of silent remission without any MS
symptoms. MS signs observed are resolved and this type named
benign MS with low disability [84], but in 40% cases of this type,
the disease is developed to MS [10,57], and this type named
malignant MS with high disability [85]. Benign MS named
clinically isolated syndrome where demyelination found without
any MS symptoms [10,86], but 30%–70% of clinically isolated
syndrome developed into MS [86].
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Primary progressive type includes progression of MS
disability and slight improvement of MS symptoms [8]. The
relapsing-remitting type (10%–20%) developed into the pri-
mary progressive type [45,56]. The relapsing-remitting type takes
nearly 10 years to convert into the primary progressive type [10].
9.3. Secondary progressive type
The patients with relapsing-remitting MS (65%) developed
into secondary progressive MS with progressive neurological
decrease without any remission [8,10]. This type has observable
relapses and slight remission [8], but the time spend from
relapsing-remitting MS to be secondary progressive MS nearly
19 years [87].
9.4. Progressive relapsing type
Progressive relapsing type includes persons who have a
stable neurological decrease and in the same time have also
obvious MS attacks. This type is the lowest common type of MS
types [8].
10. MS treatments
10.1. Relapsing-remitting MS
In 2014, nine treatments have been accepted by governing
organizations for relapsing-remitting MS type: (1) interferon b-
1a, (2) interferon b-1b, (3) mitoxantrone, (4) natalizumab, (5)
glatiramer acetate, (6) ﬁngolimod (7) dimethyl fumarate, (8)
teriﬂunomide, and (9) alemtuzumab.
The interferons and glatiramer acetate are the best treatments
used now [56], and both are effectively equal in decreasing MS
relapses by 30% [64]. However, both of them are safe for longer
therapy and MS improvement [88,89]. On the other hand,
natalizumab decreases MS relapses more efﬁcient than
interferons and glatiramer acetate but natalizumab has side
effects so it is used in MS patients who do not gave good results
with other treatments [56] or with MS advances disease [64].
Mitoxantrone due to its side effects was used in MS patients
who do not gave better results with other treatments and can be
used following interferons, glatiramer acetate and natalizumab
[56]. The disruption of natalizumab treatment in MS patients can
be followed by disease reactivation [90]. Clinically isolated
syndrome patients are treated with interferons showed declines
in MS progression to clinical MS [10,91]. The interferons and
glatiramer acetate equally effective in both children and adults
[92]. There are newly discovered treatments e.g. teriﬂunomide,
ﬁngolimod, and dimethyl fumarate but their uses are limited [93].
A mixture of chimerism and allogeneic donors is used to treat
the relapse type ofMS and autoimmune disorders in equal manner
in both animals' models and humans however the reverse of
autoimmunity is associated with a pronounced decrease in
autoreactivity of CD4+ T cells among host-type CD4+ T cells in
the spleen and lymph nodes [94]. On the other hand, intravenous
methylprednisolone pulse therapy for MS patients showed a
better results in decreasing MS symptoms following 1st, 2nd,
and 3rd clinical courses but recorded ineffectively following 4th
and 5th clinical courses of MS treatments [95].The myelin-derived altered peptide ligands treatments pre-
vent and improve MS-associated optic neuritis. The altered
peptide ligand declines pain hypersensitivity and neuro-
inﬂammation which cure the vision and this results revealed the
role of neuroimmune treatments in MS neuropathic pain and the
visual disturbance resolves in 95% of MS cases [24,96]. Other
oral MS treatments are under examination such as laquinimod
and ozanimod where laquinimod was produced in 2012 and
represents the third phase III of MS treatments [97]. Moreover,
PEGylated form of interferon-b-1a also gave a good results in
MS treatment [98].
A new treatments represents monoclonal antibodies e.g.
ocrelizumab, rituximab and ofatumumab are under investigation
[99], but with adaptable infection as side effects of these treatments,
for example progressive multifocal leukoencephalopathy appears
after natalizumab treatment [52]. The intravenous injection of
methylprednisolone (at higher doses) accelerates visual neuritis
treatment in MS patients but the MS patients with visual neuritis
can be later back to MS symptoms [24].10.2. Progressive MS
There is no treatment until now which can improve the pri-
mary and secondary progressive type of MS [56]. However, the
only treatment used is mitoxantrone for progressive MS [100].
Mitoxantrone is used carefully due to its side effects and this
treatment can slowing MS progression and decreasing MS
relapse during two years period [101,102].10.3. Treatments side effects
A lot of MS treatments side effects are recorded. Irritation is
the most common and pronounced one following subcutaneous
injections (90%) and intramuscular injections (33%) with
interferon and glatiramer acetate. A detectible hollow site in the
same place of injection due to breakdown of the adipose tissue in
injection place, this process is known as lipoatrophy [103]. On the
other side, interferons cause ﬂu-like symptoms [104], while
glatiramer acetate produces heart palpitations, chest tightness,
ﬂushing, and anxiety, its duration less than 30 min [105]. Liver
damage from interferons injections [106], which occurs in low
cases, moreover, infertility, systolic dysfunction (12%), and
acute myeloid leukemia (0.8%) from mitoxantrone [102,107],
and progressive multifocal leukoencephalopathy found after
natalizumab injections [57,108].
The ﬁngolimod treatments induces heart rate decline, hy-
pertension, macular edema, increases liver enzymes or a
decrease in lymphocyte levels [93]. On the other hand, the
teriﬂunomide treatments produce fatigue, hair loss, headaches,
limb pain, nausea, hepatic failure and fetal incomplete
development [109,110]. The side effects of dimethyl fumarate
are gastrointestinal problems and ﬂushing [93]. Furthermore,
dimethyl fumarate causes a decrease in the white blood cell
count [99,110].
All the above mentioned treatments improve some MS but
cannot stop the MS progressive disease [111]. There is a low
conﬁrmation for the efﬁcacy of person therapeutic agents
[112,113]. The exercise and psychology therapy gave good
results in MS patients [114,115], and psychology therapy
specially is effective in this matter [116].
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Fifty percent of MS patients could be use complementary
treatments [117], due to lack of any side effect but the efﬁciency
of these treatments are weak [117,118]. These treatments include
several types: vitamin D, Yoga, medicinal plants, oxygen
therapy, acupuncture and reﬂexology [117,119–122]. The
percentage of MS females patients using complementary
treatments are higher than males patients however these
females have a long MS history, more disable, in-satisfaction
with MS health programs [117].
A cannabidiol ointment obtained from Cannabis sativa is
used from MS treatment where daily treatment of cannabidiol
ointment exerts neuroprotective effects in MS animal model.
The ointment declines MS-clinical symptoms by improving hind
limbs paralysis, as well as, recovering of MS histological score
e.g. lymphocytic inﬁltration and neural demyelination in the
spinal cord tissues. In addition, cannabidiol ointment can
neutralize MS-associated damaged release of CD4 and CD8 T
cells pro-inﬂammatory cytokines and other inﬂammatory bio-
markers, oxidative damage, and apoptosis (caspase 3) [123].
Another study was carried-out used hemp seeds and primrose
oils gave good results in the treatment of clinical symptoms in
relapsing-remitting MS patients where both hemp seeds and
primrose oils improving MS disease risk and progression
specially MS patients with hereditary-related disease [124].
The melatonin administration which a natural hormone
secreted by pineal gland to MS animals' model and humans in
such a physiological dose revealed a protective action. Mela-
tonin can be also used for MS treatments in MS animals' models
and in the future can be apply into clinical practice [125].
On the other side, low-level laser therapy (LLLT) has been
used in clinically treatment of inﬂammation due to its tissue
healing and repair procedures. The LLLT has the ability to
reduce the clinical symptoms in MS animals' model and in the
same time delayed the MS incidence, moreover, prevented the
MS-associated weight loss. These good results of LLLT asso-
ciated with the down-regulation of nitric oxide levels in the
central nervous system but in the same time LLLT unsuccessful
in inhibiting lipid peroxidation and ameliorates the antioxidant
defense in MS animals' model. Furthermore, the histology re-
veals that LLLT blocked neuroinﬂammation through a decline
of inﬂammatory cells in the central nervous system, particularly
lymphocytes, and stopping the demyelination in the spinal cord
in MS animals' model so LLLT is a good therapeutic agent to
treat MS patients [126].
A telemedicine meditation was also used for MS treatments
including assessments of quality of life, anxiety, and depression
level, moreover, assessments of mindfulness level, quality of
sleep and fatigue level will be considered secondary outcome
measures [127]. In the same direction, susceptibility weighted
imaging is a new imaging technique where the imaging very
high sensitive to hemorrhagic constituents, however, the
sensitivity of this imaging provide to detect microvasculature
with high precision inside the veins with highly accurate
detection, susceptible grade and continues observing of MS
progression. Furthermore, this imaging can observe any
change in blood ﬂow and vascular defects. This imaging can
deﬁne the small lesions, axon damage, the exact place of these
lesions which can be of more beneﬁcial for MS treatments [128].
MS patients are characteristic by muscle softness and
exhaustion due to the decrease of MS normal daily life activity.MS treatments increase and improve the MS muscle strength
through practicing exercise, where exercise improves different
aspects of MS patients such as: motor and cognitive functions,
exhaustion, and life mode and activity. The exercise diminishes
the MS-related complications such as: muscle strength, func-
tional capability, timed up and go test, and MS-related EDSS
test [129].
The protein gelsolin is the protein No. 4 among most rich
body protein in the human body. In MS animals' model, gelsolin
protein decreases in the blood while its concentration increased
in the animals' brain. On the other hand, the recombinant human
form of gelsolin protein decreased extracellular actin and mye-
loperoxidase activity in the brain which lead to decrease in MS
disease activity and lowest clinical symptoms which suggest the
beneﬁcial therapeutic role of gelsolin in MS [130].
Another new trend of MS treatment is developed in the last
decade such as stem cell therapy but still in the early steps [131].
The administration of skin-derived mesenchymal stem cells
(MSCs) is able to alleviate the clinical score of MS animal
model by inhibiting the differentiation of Th17 cells where the
TNF-a is a critical cytokine for promoting Th17 cell differen-
tiation. The activated skin-derived MSCs produced high amount
of soluble TNF receptor 1, which neutralized TNF-a and
inhibited Th17 cell polarization [132]. The efﬁcacy of MSCs-
based therapy for MS likely depends on the number of cells
that home to inﬂamed tissues and on the controlled production of
paracrine and immunomodulatory factors. The treatment with
MSCs exhibited a superior therapeutic function over native
(unmodiﬁed) MSCs, evidenced by signiﬁcantly improved mye-
lination and decreased lymphocytes inﬁltration into the white
matter of the spinal cord, so MSCs could potentially be utilized
to increase the effectiveness of MSC-based therapy for MS [133].
11. Conclusions
MS is a complex disease which characterized by a wide
phenotypic variability where genetic and environmental factors
communicate to induce MS. The changes in HLA system related
genes in chromosome 6 induced MS symptoms. The physio-
logical pattern of MS includes two main steps: (1) myelin sheath
destruction and formation of lesions in the central nervous sys-
tem, (2) inﬂammation. The relapsing-remitting, primary pro-
gressive, secondary progressive, and progressive relapsing are
the four principal types of MS. The interferons and glatiramer
acetate are the main treatments for relapsing-remitting MS type
while mitoxantrone is the treatment for progressive MS type.
Vitamin D, Yoga, medicinal plants, oxygen therapy, acupunc-
ture and reﬂexology are complementary treatments used.
Multi-drug therapy is recommended and need future in-
vestigations where two or more drugs with similar or different
mechanisms of action and is known as a more efﬁcient way to
provide good ways for new drugs delivery. In the other way, a
combination of drug–drug, drug–nutraceutical, and drug–gene
can provide a good source for MS discovering new treatments.
On the other hand, the future efforts would be well value
targeting the researches correlated with pharmacogenetic, as it is
very important in MS diagnosis and treatments to determine the
patients' genetic background to deﬁne the speciﬁc and accurate
treatments for MS patients so more researches are needed in this
direction in the future.
There is an urgent need to connect MS behavior into physical
activity and exercise training especially those with progressive
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physical exercise play a vital role in increasing physical activity
and exercise to promote the MS treatments.
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